In clinical trials of Nasonex, 3774 adult and adolescent allergy patients (patients 12 years and older) were randomly divided into two groups. The patients in the experimental group received 200 μg of Nasonex, while the patients in the control group received a placebo. Of the 2103 patients in the experimental group, 547 reported headaches as a side effect. Of the 1671 patients in the control group, 368 reported headaches as a side effect. It is known that over 10 million Americans who are 12 years and older are allergy sufferers. Is there significant evidence to conclude that the proportion of Nasonex users who experienced headaches as a side effect is greater than the proportion in the control group at the 0.05 level of significance?